

## HEDIS 2020 CODING GUIDE

In addition to the coding guide, care gap reports can be produced to identify members with gaps in care according to HEDIS specifications. The Health Plan provider engagement representatives can distribute gap reports to primary care physicians. Clinical documentation to support HEDIS measures can be submitted via fax to 1.304.433.8208 or by contacting your provider engagement representative.

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT
PREVEN	NTION AND SCREENIN	IG			
АВА	Adult BMI Assessment	ALL	Percentage of members 18-74 who had their BMI and weight documented at an outpatient visit within the past 2 years *For members younger than 20 years of age documentation must be a BMI percentile with height and weight	<ul> <li>BMI: ICD-10: Z68.1, Z68.20-68.39, Z68.41-68.45</li> <li>BMI Percentile: ICD-10: Z68.51-68.54</li> </ul>	
wcc	Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents	Commercial & Medicaid	Percentage of members 3-17 who had an outpatient visit with a PCP or OB/GYN which included evidence of BMI documentation with corresponding height & weight, counseling for nutrition and/or counseling for physical activity during the measurement year	BMI Percentile: ICD-10: Z68.51-         68.54         Nutrition Counseling: CPT: 97802-         97804; HCPCS: S9470, S9452, S9449,         G0270, G0271, G0447; ICD-10:         Z71.3         Physical Activity Counseling:         HCPCS: S9451, G0447; ICD-10:         Z02.5, Z71.82	

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT
PREVE	NTION AND SCREENIN	IG, CONT.			
CIS	Childhood Immunization Status	Commercial & Medicaid	Percentage of children two years of age with appropriate childhood immunizations including at least: • 4 DTAP • 3 IPV • 1 MMR • 3 HIB • 3 Hep B • 1 VZV • 4 PCV • 1 Hep A • 2-3 dose Rotavirus vaccines • At least 2 Influenza vaccines	DTaP: CPT: 90698, 90700, 90721, 90723 IPV: CPT: 90698, 90713, 90723 MMR: CPT: 90707, 90710 Hib: CPT: 90644-90648, 90698, 90721, 90748 Hepatitis B: CPT: 90723, 90740, 90744, 90747, 90748; HCPCS: G0010 VZV: CPT: 90710, 90716 Pneumococcal Conjugate: CPT: 90670 HCPCS: G0009 Hepatitis A: CPT: 90633 Rotavirus (2 dose schedule): CPT: 90681 Rotavirus (3 dose schedule): CPT: 90681 Rotavirus (3 dose schedule): CPT: 90680 Influenza: CPT: 90655, 90657, 90661, 90662, 90673, 90685-90688; HCPCS: G0008 Exclusion (Anaphylactic Reaction): ICD-10: T80.52XA, T80.52XD, T80.52XS	
IMA	Immunizations for Adolescents	Commercial & Medicaid	Percentage of adolescents 13 years of age with appropriate immunizations including at least: • 1 meningococcal vaccine between 11th and 13th birthdays • 1 Tdap between 10th and 13th birthdays; • 2 HPV vaccines at least 146 days apart <u>or</u> 3 HPV vaccines on different dates of service between 9th and 13th birthdays	Meningococcal: CPT: 90734 Tdap: CPT: 90715 HPV: CPT: 90649, 90650, 90651 Exclusion (Anaphylactic Reaction): ICD-10: T80.52XA, T80.52XD, T80.52XS	

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT			
PREVE	PREVENTION AND SCREENING, CONT.							
BCS	Breast Cancer Screening	ALL	Percentage of women 50-74 years of age who had a mammogram any time on or between Oct 1 two years prior to the measurement year and Dec 31 of the measurement year	Mammography: CPT: 77055-77057, 77061-77063, 77065-77067; HCPCS: G0202, G0204, G0206 Exclusion (Bilateral Mastectomy): ICD-10: OHTV0ZZ, ICD-9: 85.42, 85.44, 85.46, 85.48				
CCS	Cervical Cancer Screening	Commercial & Medicaid	Percentage of women 21-64 years of age who had a Pap test within the past 3 years or women 30-64 who had cervical cytology/high-risk human papillomavirus (hrHPV) cotesting within the past 5 years	Cervical Cytology: CPT: 88141- 88143, 88147, 88148, 88150, 88152- 88154, 88164-88167, 88174, 88175 HPV: CPT: 87620-87622, 87624- 87625 HCPCS: G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091 Exclusion (Hysterectomy): CPT: 51925, 56308, 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200, 58210, 58240, 5860, 58262, 58263, 58267, 58270, 58275, 58280, 58285, 58290-58294, 58548, 58550, 58552- 58554, 58570-58575, 58951,58953, 58954,58956, 59135				
COL	Colorectal Cancer Screening	Commercial & Medicare	Percentage of members 50-75 years of age who had appropriate screening for colorectal cancer including at least <u>one</u> of the following: • FOBT during the measurement year • Flexible sigmoidoscopy within the past 5 years • Colonoscopy within the past 10 years • CT colonography within the past 5 years • FIT-DNA within the past 3 years	FOBT: CPT: 82270, 82274; HCPCS:         G0328         FIT-DNA: CPT: 81528; HCPCS:         G0464         CT Colonography: CPT: 74261-         74263         Flexible Sigmoidoscopy: CPT:         45330-45335, 45337-45342, 45345-         45347, 45349, 45350; HCPCS:         G0104         Colonoscopy: CPT: 44388-44394,         44397, 44401-44408, 45355, 45378-         45393, 45398; HCPCS: G0105,         G0121         Exclusion (Colorectal Cancer):         HCPCS: G0213, G0214, G0215,         G0231; ICD-10: C18.0-C18.9, C19,         C20, C21.8, C78.5, Z85.038, Z85.048         (Total Colectomy): CPT: 44150-         44153, 44155-44158, 44210-44212				

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT
PREVE	NTION AND SCREENIN	IG, CONT.			
CHL	Chlamydia Screening in Women	Commercial & Medicaid	Sexually active women 16-24 with annual chlamydia screening	<b>CPT:</b> 87110, 87270, 87320, 87490- 87492, 87810	
			Percentage of adults 66 years and older who had <u>each</u> of the following during	<b>Advance Care Planning: CPT:</b> 99483, 99497 <b>HCPCS:</b> \$0257	1123F, 1124F, 1157F, 1158F
СОА	Care for Older Adults	Medicare SNP	<ul> <li>the measurement year:</li> <li>Advance care planning</li> <li>Medication review (includes a</li> </ul>	Medication Review: CPT: 90863, 99483, 99605, 99606 Medication List: HCPCS: G8427	1160F 1159F
	Medication review (include medication list and a review     Functional status assessment	<ul> <li>Medication list and a review)</li> <li>Functional status assessment</li> <li>Pain assessment</li> </ul>	Functional Status Assessment: CPT: 99483; HCPCS: G0438, G0439	1170F	
				Pain Assessment:	1125F, 1126F
RESPIR	ATORY CONDITIONS				
CWP	Appropriate Testing for Pharyngitis	Commercial, Medicaid, & Medicare	Percentage of members 3 years or older diagnosed with pharyngitis, prescribed an antibiotic, and tested for strep	<b>CPT:</b> 87070, 87071, 87081, 87430, 87650-87652, 87880	
PCE	Pharmacotherapy Management of COPD Exacerbation	ALL	Members dispensed systemic corticosteroid within 14 days or bronchodilator within 30 days of an acute inpatient discharge or ED encounter with a principal diagnosis of COPD	Dispensed Systemic Corticosteroid and Bronchodilator	
мма	Medication Management for People with Asthma	Commercial & Medicaid	Percentage of members 5-64 years who remain on an asthma controller for at least 75% of their treatment period	Frequency of Prescribed Preferred Asthma Medications: antiasthmatic combinations, antibody inhibitor, inhaled steroid combinations, inhaled corticosteroids, leukotriene modifiers, mast cell stabilizers, methylxanthines	

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT
RESPIRA	ATORY CONDITIONS,	CONT.			
AMR	Asthma Medication Ratio	Commercial & Medicaid	Percentage of members 5-64 years of age with asthma who had a ratio of controller medications to total asthma medications of .5 or greater	Asthma Controller and Reliever Medications: Antiasthmatic combinations, antibody inhibitors, inhaled steroid combinations, inhaled corticosteroids, leukotriene modifiers, mast cell stabilizers, methylxanthines; short acting, inhaled beta-2 agonists	
CARDI	OVASCULAR				
Свр	Controlling High Blood Pressure	ALL	Percentage of members 18-85 years of age with a diagnosis of hypertension and whose blood pressure was controlled (<140/90 mm Hg) during the measurement year		<b>Systolic:</b> 3074F, 3075F, 3077F <b>Diastolic:</b> 3078F, 3079F, 3080F
РВН	Persistence of Beta-Blocker Treatment After a Heart Attack	ALL	Percentage of members 18 years or older who were discharged with a diagnosis of acute myocardial infarction and received a beta-blocker treatment for 6 months after discharge	<b>Beta Blocker Medications:</b> Noncardioselective beta- blockers, Cardioselective beta- blockers, Antihypertensive combinations	
SPC	Statin Therapy for Patients with Cardiovascular Disease	ALL	The percentage of males 21-75 years of age and females 40-75 years of age with clinical atherosclerotic cardiovascular disease (ASCVD) and were dispensed at least one high or moderate intensity statin medication during the measurement year and remained on medication for at least 80% of the treatment period	High intensity statin therapy medications Moderate intensity statin therapy medications	

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT
DIABET	ES				
				HbA1c Tests: CPT: 83036, 83037	3044F, 3045F, 3046F
				Nephropathy Screening: CPT: 81000-81003, 81005, 82042-82044, 84156	3060F, 3061F, 3062F
CDC	Comprehensive Diabetes Care	ALL	The percentage of members 18-75 years of age with diabetes who had <u>each</u> of the following during the measurement year: • HbA1c (control <8.0%) • Nephropathy screening • Retinal eye exam	<b>Eye Exams: CPT:</b> 67028, 67030, 67031, 67036, 67039-67043, 67101, 67105, 67107, 67108, 67110, 67113, 67121, 67141, 67145, 67208, 67210, 67218, 67220, 67221, 67227, 67228, 92002, 92004, 92012, 92014, 92018, 92019, 92134, 92225-92228, 92230, 92235, 92240, 92250, 92260, 99203-99205, 99213-99215, 99242- 99245 HCPCS: S0620, S0621, S3000	2022F, 2024F, 2026F, 3072F
			Blood pressure control (<140/90)	Blood pressure control:Systolic: 3075F, 30 Diastolic:	Systolic: 3074F, 3075F, 3077F Diastolic: 3078F, 3079F, 3080F
SPD	Statin Therapy for Patients with Diabetes	ALL	The percentage of diabetic members 40-75 years of age who do <b>not</b> have clinical atherosclerotic cardiovascular disease (ASCVD) and were dispensed at least one statin medication during the measurement year and remained on medication for at least 80% of the treatment period	High intensity statin therapy medications Moderate intensity statin therapy medications Low intensity statin therapy medications	

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT
MUSCI	JLOSKELETAL				
ART	Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis	Medicare	Percentage of members 18 years of age and older who were diagnosed with rheumatoid arthritis and who were dispensed at least one ambulatory prescription for a disease-modifying anti-rheumatic drug (DMARD) during the measurement year	A dispensed DMARD medication <b>or HCPCS:</b> J0129, J0135, J0717, J1438, J1600, J1602, J1745, J3262, J7502, J7515-J7518, J9250, J9260, J9310, Q5102-Q5104	
омw	Osteoporosis Management in Women Who Had Fracture	Medicare	Percentage of women 67-85 years of age who suffered a fracture and received appropriate osteoporosis treatment as indicated by <u>one</u> of the following: • Bone Mineral Density Test within 6 months of the fracture or during the inpatient stay if fracture occurred during hospitalization • Osteoporosis therapy within 6 months of the fracture • Long-acting osteoporosis therapy during the inpatient stay if fracture occurred during hospitalization • A dispensed prescription to treat osteoporosis within 6 months of the fracture	<b>CPT:</b> 76977, 77078, 77080-77082, 77085, 77086 <b>HCPCS:</b> G0130, J0630, J0897, J1740, J3110, J3489, J2794, J2680, J2426, J2358, J1631, J0401 <b>or</b> Biphosphonates or other approved agents	
BEHAV	IORAL HEALTH				
АММ	Antidepressant Medication Management	ALL	Percentage of members 18 years or older diagnosed with depression who remained on antidepressant medication for at least 6 months **This measure is a 12 month window starting on May 1 of the year prior to the measurement year and ending on April 30 of the measurement year.	Miscellaneous antidepressants, Monoamine oxidase inhibitors, Phenylpiperazine antidepressants, Psychotherapeutic combinations, SNRI antidepressants, SSRI antidepressants, Tetracycline antidepressants, Tricycline antidepressants	

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT
BEHAV	IORAL HEALTH, CONT				
ADD	Follow-Up Care for Children Prescribed ADHD Medication	Commercial & Medicaid	Percentage of children 6-12 years of age with newly prescribed ADHD medication who received the appropriate follow-up visits and medication. Appropriate visits include an initiation visit 30-day post medication and two visits within 9 months of the initiation visit. **This measure is a 12 month window starting on March 1 of the year prior to the measurement year and ending the last day of February of the measurement year.	Initiation Visit: CPT: 90791, 90792, 90832- 90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221- 99223, 99231-99233, 99238, 99239, 99251-99255, 98960-98962, 99078, 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99510; HCPCS: G0155, G0176, G0177, G0409, G0463, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013- H2020, M0064 Maintenance Visit: CPT: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 96150- 96154, 98966-99443, 99221-99223, 99231-99233, 99238, 99239, 99251-99255, 98960-98962, 99078, 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99510; HCPCS: G0155, G0176, G0177, G0409, G0463, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013-H2020, M0064	
FUH	Follow-Up After Hospitalization for Mental Illness	ALL	Percentage of discharges for members 6 years or older who were hospitalized for treatment of a mental health disorder and received appropriate follow-up visits within 7 and 30 days during the measurement year	<b>CPT:</b> 90791, 90792, 90832-90834, 90836- 90840, 90845, 90847, 90849, 90853, 90875, 90876, 96150-96154, 99221- 99223, 99231-99233, 99238, 99239, 99251-99255, 98960-98962, 99078, 99201-99205, 99211-99215, 99241- 99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401- 99404, 99411, 99412, 99483, 99510; <b>HCPCS:</b> G0155, G0176, G0177, G0409, G0463, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013-H2020, M0064	

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT
BEHAV	IORAL HEALTH, CONT	•			
FUI	Follow-up After High Intensity Care for Substance Use Disorder	ALL	Percentage of members 13 years of age and older who receive follow-up treatment within 7 and 30 days following acute inpatient hospitalization, residential treatment, or detoxification visit for substance use disorder during the measurement year	<b>CPT</b> 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 98960-98962, 98966-98969, 99078, 99201-99205, 99211-99215, 99221-99223, 99231- 99233, 99238, 99239, 99241-99245, 99251-99255, 99341-99345, 99347- 99350, 99384-99387, 99394-99397, 99401-99404, 99408, 99409, 99411, 99412, 99441-99444, 99483, 99510; <b>HCPCS:</b> H0020, H0033, J0570-J0575, J2315, Q9991, Q9992, S0109, G0155, G0176, G0177, G0396, G0397, G0409-G0411, G0443, G0463, H0001, H0002, H0004, H0005, H0007, H0015-H0019, H0022, H0031, H0034-H0037, H0039, H0040, H0047, H2000, H2001, H2010-H2020, H2035, H2036, M0064, S0201, S9480, S9484, S9485, T1006, T1012, T1015, T2048	
АРМ	Metabolic Monitoring for Children and Adolescents on Antipsychotics	Commercial & Medicaid	Percentage of children and adolescents 1-17 years of age who had two or more antipsychotic prescriptions and had metabolic testing including at least <u>one</u> of the following during the measurement year: • Blood glucose testing • Cholesterol testing	<b>CPT:</b> 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951, 83036, 83037, 82465, 83718, 84478, 80061, 83700, 83701, 83704, 83721	
POD	Pharmacotherapy for Opioid Use Disorder	ALL	Percentage of new opioid use disorder pharmacotherapy events with OUD pharmacotherapy for 180 days or more days among members age 16 and older with this diagnosis	Naltrexone oral medications, Naltrexone Injection medications list, Buprenorphine Oral medications list, Buprenorphine Implant Medications list, Buprenorphine Naloxone Medication list	

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT
BEHAV	IORAL HEALTH, CONT				
FUM	Follow up After Emergency Department Visit for Mental Illness	ALL	Percentage of ED visits for members 6 years of age and older with a principal diagnosis of mental illness or intentional self-harm who had a follow-up visit for mental illness	Follow-up visit for mental illness (follow-up within 7 days of discharge; follow-up within 30 days of discharge)	
FUA	Follow up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence	ALL	Percentage of emergency department visits for members 13 years of age or older with a principal diagnosis of alcohol or other drug dependence who had a follow up for AOD during the measurement year	Follow-up visit for AOD (follow-up within 7 days of discharge; follow- up within 30 days of discharge)	
SSD	Diabetes Screening for People with Schizophrenia or Bipolar Who Are Using Antipsychotic Medications	Medicaid	Percentage of members 18-64 years of age with schizophrenia, schizoaffective disorder or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test during the measurement year	HbA1c Tests: CPT: 83036, 83037 Antipsychotic Medication: Aripiprazole, Asenapine,Brexpiprazole, Cariprazine, Clozapine, Haloperidol, lioperidone, Loxapine, Lurisadone, Molindone, Olanzapine, Paliperidone, Quetiapine, Quetiapine fumerate, Risperidone, Ziprasidone, Chlorpromazine, Fluphenazine, Perphenazine, Prochlorperazine, Thioridazine, Trifluoperazine, Amitriptyline-perphenazine, Thiothizene, Aripiprazole, Fluenazine decanoate, Haloperidol decanoate, Olanzapine, Paliperidone palmitate, Risperidone	

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT
BEHAV	IORAL HEALTH, CON	r.			
SAA	Adherence to Antipsychotic Medications for Individuals with Schizophrenia	ALL	Percentage of members 18 years and older during the measurement year with schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period	Dementia Medication: Donepezil, Galantamine, Rivastigmine, Memantime Antipsychotic Medications: Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Haloperidol, lioperidone, Loxapine, Lurisadone, Molindone, Olanzapine, Paliperidone, Quetiapine, Quetiapine fumarate, Risperidone, Ziprasidone, Chlorpromazine, Fluphenazine, Perphenazine, Prochlorperazine, Thioridazine, Trifluoperazine, Amitriptyline- perphenazine, Thiothixene Long acting injections: Risperidone, Aripiprazole, Fluphenazine decanoate, Haloperidol deconoate, Olanzapine Paliperidone palmitate	
MEDIC	ATION MANAGEMEN	T			
TRC	Transitions of Care	Medicare	Percentage of discharges during the measurement year for members 18 years of age and older who had <u>each</u> of the following: • Notification of inpatient admission (on day of admission or following day) • Receipt of discharge information (on day of discharge or following day) • Patient engagement after inpatient discharge (within 30 days after discharge) • Medication reconciliation post- discharge (within 30 days after	Patient Engagement: CPT: 99201-         99205, 99211-99215, 99241-99245,         99341-99345, 99347-99350, 99381-         99387, 99391-99397, 99401-99404,         99411, 99412, 99429, 99455,         99456, 99483, 98966-98968,         99441-99443; HCPCS: H0402,         G0438, G0439, G0463, T1015         Medication Reconciliation:         99483, 99495, 99496	1111F

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT
MEDIC	AL MANAGEMENT, C	ONT.			
MRP	Medication Reconciliation Post-Discharge	Medicare	Percentage of discharges during the measurement year for members 18 years of age and older for whom medications were reconciled on or within 30 days of discharge	<b>CPT:</b> 99483, 99495, 99496	1111F
FMC	Follow up After Emergency Department Visit for People with Multiple High-Risk Chronic Conditions	Medicare	Percentage of members 18 years and older with multiple high-risk chronic conditions who had a follow-up service within 7 days of an ED visit during the measurement year	Follow-up visit within 7 days of ED visit	
OVERU	ISE/APPROPRIATENES	S			
PSA	Non- Recommended PSA-Based Screening in Older Men	Medicare	Percentage of men 70 years and older during the measurement year who were screened unnecessarily for prostate cancer using prostate-specific antigen (PSA)-based screening **A lower rate indicates better performance	CPT: 84152-84154; HCPCS: G0103	
URI	Appropriate Treatment for Upper Respiratory Infection	ALL	Percentage of children 3 months of age and older diagnosed with upper respiratory infection diagnosis and <b>not</b> dispensed an antibiotic**This measure has a 12-month window starting July 1 of the year prior to the measurement year and ending June 30 of the measurement year	Antibiotic Prescriptions: Aminopenicillins, Beta-lactamase inhibitors, first generation cephalosporins, folate antagonist, lincomycin derivatives, macrolides, miscellaneous antibiotics, natural penicillins, penicillinase-resistant penicillins, quinolones, second generation cephalosporins, sulfonamides, tetracyclines, third generation cephalosporins	

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT		
OVERU	OVERUSE/APPROPRIATENESS, CONT.						
AAB	Avoidance of Antibiotic Treatment for Acute Bronchitis	ALL	Percentage of members 3 months and older diagnosed with acute bronchitis who were <b>not</b> dispensed an antibiotic **This measure has a 12-month window starting July 1 of the year prior to the measurement year and ending June 30 of the measurement year	Antibiotic Prescriptions: Aminoglycosides, aminopenicillins, antipseudomonal penicillins, beta-lactamase inhibitors, first generation cephalosporins, fourth generation cephalosporins, ketolides, lincomycin derivatives, macrolides, miscellaneous antibiotics, natural penicillins, penicillinase-resistant penicillins, quinolones, rifamycin derivatives, second generation cephalosporin, sulfonamides, tetracyclines, third generation cephalosporins, urinary anti- infectives			
LBP	Use of Imaging Studies for Low Back Pain	Commercial & Medicaid	Percentage of members with a primary diagnosis of low back pain during the measurement year who did <b>not</b> have an imaging study within 28 days of diagnosis	<b>CPT:</b> 72020, 72052, 72100, 72110, 72114, 72120, 72131-72133, 72141, 72142, 72146-72149, 72156, 72158, 72200, 72202, 72220			
DAE	Use of High-Risk Medications in Older Adults	Medicare	The percentage of members over 66 years of age who had at least two dispensing events for the same high- risk medication during the measurement year **A lower rate indicates better performance	Members who had two dispensing events for the same high-risk medication			

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT	
OVERUSE/APPROPRIATENESS, CONT.						
DDE	Potentially Harmful Drug-Disease Interaction in Older Adults	Medicare	Percentage of members 65 years or older who have evidence of an underlying disease, condition or heath concern who were dispensed an ambulatory prescription for a contraindicated medication during the measurement year **A lower rate indicates better performance	Members identified with falls or hip fractures: Dispensed an ambulatory prescription for an anticonvulsant, antipsychotic, benzodiazepine, nonbenzodiazepine hypnotic, SSRI, SNRI, or tricylic antidepressant Members diagnosed with dementia or a dispensed dementia medication: Dispensed an ambulatory prescription for an antipsychotic, benzodiazepine, nonbenzodiazepine hypnotic, tricylic antidepressant, or anticholinergic agent Members diagnosed with chronic renal failure: Dispensed an ambulatory prescription for a nonaspirin NSAID or Cox-2 NSAID		
HDO	Use of Opioids at High Dose	ALL	Proportion of members 18 years and older who received prescription opioids at a high dose for >15 days during the measurement year.	Members who received prescription opioids at high dosage for ≥ 15 days		
UOP	Use of Opioids from Multiple Providers	ALL	Proportion of members 18 years and older, receiving prescription opioids for ≥15 days during measurement year who received opioids from multiple providers	Receiving prescription opioids at high dosage for ≥ 15 days, received from mulitple providers 1. Multiple prescribers (four or more prescribers) 2. Multiple pharmacies (four or more pharmacies) 3. Multiple prescribers & pharmacies (both four or more prescribers <b>and</b> four or more pharmacies)		

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT	
OVERUSE/APPROPRIATENESS, CONT.						
COU	Risk of Continued Opioid Use	ALL	Percentage of members 18 years or older who have a new episode of opioid use during the measurement year that puts them at risk for continued opioid use	Have new episode of opioid use that puts them at risk for continued opioid use. 1. Percentage of members whose new episode of opioid use lasts at least 15 days in a 30-day period 2. Percentage of members whose new episode of opioid use last at least 31 days in 62-day period		
ACCES	S/AVAILABILITY OF C					
САР	Children and Adolescents; Access to Primary Care Practitioners	Commercial & Medicaid	Percentage of members 1-6 years of age who had a visit with a PCP during the measurement year. Children and adolescents 7-19 years of age who had a visit with a PCP during the measurement year or the year prior to the measurement year.	<b>CPT:</b> 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347- 99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99429, 99483 <b>HCPCS:</b> G0402, G0438, G0439, G0463, T1015 <b>ICD-10</b> : Z00.00, Z00.01, Z00.121, Z00129, Z00.3, Z00.5, Z00.8, Z02.0Z02.6, Z02.71, Z02.79, Z02.81-Z02.83, Z02.89, Z02.9, 76.1, Z76.2		
ААР	Adults' Access to Preventive/ Ambulatory Health Services	ALL	The percentage of members 20 years or older who had an ambulatory or preventive care visit during: • the measurement year (Medicaid and Medicare) or • the measurement year or the two years prior (Commercial)	<b>CPT:</b> 98966-98968, 99441-99443, 92002, 92004, 92012, 92014, 99201-99205, 99211-99215, 99241- 99245, 99304-99310, 99315, 99316, 99318, 99324-99328, 99334-99337, 99341-99345, 99347-99350, 99381- 99387, 99391-99397, 99401-99404, 99411, 99412, 99420, 99429; <b>HCPCS:</b> G0402, G0438, G0439, G0463, T1015, S0620, S0621; <b>ICD-</b> <b>10</b> : Z00.00, Z00.01, Z00.121, Z00.129, Z00.3, Z00.5, Z00.8, Z02.0- Z02.6, Z02.71, Z02.79, Z02.81- Z02.83, Z02.89, Z02.9, Z76.1, Z76.2		
ADV	Annual Dental Visit	MHT	Percentage of members 2-20 years of age who had a dental visit during the measurement year	Annual dental visit with <b>a dental</b> <b>provider</b>		

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT		
OVERU	OVERUSE/APPROPRIATENESS, CONT.						
IET		Initiation and		Percentage of members 13 years of age and older with a new diagnosis of	Initiation of AOD treatment: An inpatient admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of diagnosis -or- CPT: 98966-98968, 99441-99443		
	Engagement of Alcohol and Other Drug Dependence Treatment	ALL	alcohol or drug dependence during the measurement year who had initation and engagement of treatment visits within 14 and 34 days of diagnosis.	<b>Engagement of AOD treatment:</b> Initiation of AOD treatment and two or more inpatient admissions, outpatient visits, intensive outpatient encounters or partial hospitalizations with any AOD diagnosis within 34 days after date of the initiation encounter <b>-or- CPT:</b> 98966-98968, 99441-99443			
PPC	Prenatal and	Commercial	Percentage of deliveries with	<b>Timeliness of prenatal care:</b> a prenatal visit in the first trimester or within 42 days of enrollment			
	Postpartum Care	& Medicaid	care	<b>Postpartum care:</b> a postpartum visit between 7 and 84 days after delivery			
APP	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics	Commercial & Medicaid	Percentage of children and adolescents 1-17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment during the measurement year	<b>CPT:</b> 90832-90834, 90836-90840, 90845-90847, 90849, 90853, 90875, 90875, 90880; <b>HCPCS:</b> G0176, G0177, G0409-G0411, H0004, H0035-H0040, H2000, H2001, H2011-H2014, H2017-H2020, S0201, S9480, S9484, S9485			

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT		
USE OF	USE OF SERVICES						
W34	Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life	Commercial & Medicaid	Percentage of members 3-6 years of age who received one or more well- child visits with PCP during the measurement year	<b>CPT:</b> 99381-99385, 99391-99395, 99461; <b>HCPCS:</b> G0438, G0439; <b>ICD-10:</b> Z00.00, Z00.01, Z00.110, Z00.111, Z00.121, Z00.129, Z00.5, Z00.8, Z02.0-ZZ02.6, Z02.71, Z02.82, Z76.1, Z76.2			
AWC	Adolescent Well- Care Visits	Commercial & Medicaid	Percentage of members 12-21 years of age who received one or more well- child visit with PCP or OB/GYN during the measurement year	<b>CPT:</b> 99381-99385, 99391-99395, 99461; <b>HCPCS:</b> G0438, G0439; <b>ICD-10</b> : Z00.00, Z00.01, Z00.110, Z00.111, Z00.121, Z00.129, Z00.5, Z00.8, Z02.0-ZZ02.6, Z02.71, Z02.82, Z76.1, Z76.2			
PCR	Plan All Cause Readmissions	ALL	Members 18 years of age and older who had an acute discharge with an unplanned readmission within 30 days during the measurement year				
<b>RISK A</b>	DJUSTED UTILIZATION						
AHU	Acute Hospital Utilization	Commercial & Medicare	Members 18 and older, the acute impatient and observation stay discharges during the measurement year				
EDU	Emergency Department Utilization	Commercial & Medicare	Members 18 years and older, emergency department visits during the measurement year				

Code	Measure Title	Product Line	Description	Coding (Identifying Numerator)	Category II Codes-CPT		
MEASU	MEASURES COLLECTED THROUGH CAHPS HEALTH PLAN SURVEY						
FVA	Flu Shots for Adults	Commercial & Medicaid	Percentage of members 18-64 years who received a flu shot in the last year				
FVO	Flu Shots in Older Adults	Medicare	Percentage of members 65 years and older who received a flu shot in the last year				
FRM	Fall Risk Management	Medicare	Assesses different facets of fall risk management	Discussing and Managing Fall Risk			
MUI	Management Urinary Incontinence in Older Adults	Medicare	Assesses the management of urinary incontinence in older adults	Discussing Urinary Incontinence and Treatment			
οτο	Osteoporosis Testing in Women	Medicare	Percentage of women 65 years and older who received a bone density test	Reported ever having received a bone density test to check for osteoporosis			
ΡΑΟ	Physical Activity in Older Adults	Medicare	Assesses different facets of promoting physical activity in older adults	Discussing and Advising Physical Activity			
PNU	Pneumonia Vaccine Status	Medicare	Percentage of members 65 years and older who received a pneumococcal vaccine during the measurement year				
MSC	Medical Assistance with Smoking Cessation	ALL	Assesses different facets of providing medical assistance with smoking and tobacco cessation	Advising Smokers and Tobacco Users to Quit, Discussing Cessation Medications, and Discussing Cessation Strategies			